share_log

财信证券:看好医美板块配置的性价比

Securities Times ·  May 21 14:45

证券时报网讯,财信证券研报指出,受去年同期高基数影响,医美板块持续承压,但重组胶原等赛道高景气延续。短期来看,重组胶原、水光、肉毒等热门赛道高增长势头不变,扩渠道、扩品类的战略打法仍在不断驱动业绩增长。长期来看,渗透率提升、轻医美化率提升、国产化率提升逻辑持续演绎,供需双发展局面延续,看好医美板块配置的性价比。

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment